GE Healthcare and Sophia Genetics have announced that they are collaborating to better target and match treatments to each patient's genomic profile and cancer type using artificial intelligence (AI).
The companies aim to develop new AI-powered analytics and workflow solutions to serve both the clinical and biopharmaceutical markets. They will combine data from GE Healthcare's Edison AI platform and the Sophia DDM software-as-a-service cloud-based platform.
